Back in mid-January, Nancy Pelosi updated her stock portfolio, as revealed by a periodic transaction report retrieved by Finbold’s congressional trading radar.
Receive Signals on US Congress Members' Stock Trades
Stay up-to-date on the trading activity of US Congress members. The signal triggers based on updates from the House disclosure reports, notifying you of their latest stock transactions.
When the former Speaker of the House makes a purchase, the markets react. In the case of Tempus AI stock (NASDAQ: TEM), the effect was all the more pronounced, as it had flown under the radar until then.
TEM stock saw a 154.45% surge after Nancy Pelosi’s purchase was made public, having gone from $35.15 per share to $89.44. Since then, it has crashed by 54.18%, and was trading at $40.91 at press time on Tuesday, April 22.
At present, Nancy Pelosi’s latest stock bet is still up 21.17% on a year-to-date (YTD) basis. While a vast majority of the stock’s recent gains have been undone, one Wall Street analyst believes that there’s much more room to grow — and that TEM stock could reach prices as high as $60 going forward, which would equate to a 46% rally from current prices.
Nancy Pelosi’s latest stock bet poised for growth — but a repeat surge is unlikely
To be more specific, BTIG’s Mark Massaro initiated coverage on Tempus AI stock with a ‘Buy’ rating on Monday, April 21.
In a note shared with investors, the analyst cited the company’s rapidly growing precision medicine platform, as well as plans to expand beyond its initial focus on oncology into other areas of medicine as key drivers behind his decision. Massaro is confident that the convergence of generative artificial intelligence (GenAI) and healthcare is a winning combination — and that Tempus AI has the potential to scale well in the future across multiple disease verticals.
Moreover, Massaro highlighted that, with one of the largest molecular libraries of cancer patients globally, the business is well-positioned to meet its strategic goal of becoming the leading data monetization platform in precision medicine.
At present, Nancy Pelosi’s latest stock bet seems like a solid buy. While it likely won’t see such intense moves to the upside going forward, a more conservative, long-term bullish approach is still warranted.
Featured image via Shutterstock
